103P Genome-wide CRISPR and drug screening reveal MCL1 as an actionable target in clear cell sarcoma

ESMO rare cancers. 2026 Open access

Read full text
Authors: Christian Britschgi, L. Leuenberger, Larissa Isenegger, Yanjiang Chen, M. Burri, Sarah Kollar, Lara Planas‐Paz, Peter K. Bode, Agnieszka Woźniak, S. Bauer, Patrick Schoeffski, Chantal Pauli
DOI: 10.1016/j.esmorc.2026.100309
Cited by: 0

Abstract

Clear Cell Sarcoma (CCSA) is an ultra-rare sarcoma characterized by specific gene fusions EWSR1::ATF1 or EWSR1::CREB1. It is highly resistant to systemic therapy and radiotherapy. We aimed to uncover new therapeutic strategies by combining CRISPR/Cas9 knock-out and functional drug screening.

Fields of Study & Subjects

Sarcoma Diagnosis and Treatment Chromatin Remodeling and Cancer CRISPR and Genetic Engineering

Publication details

Journal / source
ESMO rare cancers.
Volume
5
Pages
100309–100309
Publication date
1 March 2026
Language
EN